CNJ-016 market forecast points to steady growth through 2035

The Business Research Company projects the CNJ-016 market will expand through 2035, driven by rising immunodeficiency cases, smallpox vaccine use, and growing interest in personalized medicine. North America led the market in 2025, while Asia-Pacific is expected to grow fastest over the forecast period.

Why it matters: - CNJ-016 is a niche but important biologic used to reduce severe complications from smallpox vaccination. - Demand could rise as governments expand biodefense planning and as more patients need protection from vaccinia-related reactions. - The market also reflects broader growth in plasma-derived therapies and targeted immune treatments.

What happened: - The Business Research Company published a CNJ-016 market report covering market size, trends, and a global forecast for 2026-2035. - The report says the CNJ-016 market is growing and is expected to keep expanding over the forecast period. - The report identifies North America as the largest regional market in 2025. - The report projects Asia-Pacific will post the fastest growth rate during the forecast period. - The company offers a free sample of the report. - The company also provides the full market report.

The details: - CNJ-016 is a vaccinia immune globulin, or VIG, derived from human plasma. - CNJ-016 contains high levels of antibodies that target the vaccinia virus. - CNJ-016 is used to treat severe complications from smallpox vaccination, including eczema vaccinatum. - CNJ-016 is intended for patients with life-threatening reactions to vaccinia virus exposure, including people with eczema or weakened immune systems. - The report links historic growth to better management of smallpox vaccine adverse events, advances in plasma fractionation, emergency regulatory approvals, biodefense preparedness, and public health crisis planning. - The report says future growth will be supported by renewed biodefense investment, larger national stockpiles, improved plasma collection systems, more immunocompromised patients, and stronger global health security measures. - Forecast-period trends include more focus on managing smallpox vaccine complications, strategic stockpiling of vaccinia immune globulin, expanded use of plasma-derived antibody therapies, and government-backed biodefense programs. - Rising immunodeficiency disease prevalence is a major growth driver because CNJ-016 provides passive immunity for vulnerable patients. - Immunodeficiency UK reported in November 2025 that more than 5,000 people in the United Kingdom had been diagnosed with one of more than 450 primary immunodeficiency disorders. - The report says smallpox vaccination trends are also supporting demand for CNJ-016. - By May 2023, the US Centers for Disease Control and Prevention said 1.2 million doses of the JYNNEOS vaccine had been given, covering about 37% of the at-risk population with a first dose and 23% with a second dose. - The report ties CNJ-016 growth to personalized medicine, which uses genetic, environmental, and lifestyle factors to tailor care. - In February 2024, the Personalized Medicine Coalition said the US Food and Drug Administration approved 16 new personalized treatments for rare diseases in 2023, up from six in 2022. - The report covers Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa.

Between the lines: - The market is being shaped less by everyday demand and more by preparedness planning, vaccine safety needs, and stockpile strategy. - CNJ-016 sits at the intersection of public health defense and rare-disease care, which can make demand lumpy but strategically important. - The report’s emphasis on plasma-derived therapy and immunocompromised patients suggests suppliers and public agencies are watching the same structural risk factors.

What's next: - The report points to continued market expansion as biodefense spending, vaccine preparedness, and immune-disorder awareness increase. - The fastest growth is expected in Asia-Pacific, signaling broader geographic adoption beyond the current North American center of gravity. - The report adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics, and updated trend analysis to its 2026 edition.

The bottom line: - CNJ-016 is likely to remain a specialized but strategically relevant market, with growth driven by public health preparedness rather than broad consumer demand.